Klik Technologies

Click Therapeutics is a pioneer in the field of digital therapeutics, developing software-based treatments for patients with unmet medical needs. The company's proprietary Clickometrics platform utilizes data science and behavioral clinical validation to create prescription digital therapeutics (PDTs) that can be used independently or in conjunction with traditional pharmacotherapies. Click has established significant partnerships with major pharmaceutical companies like Otsuka and Boehringer Ingelheim to co-develop and commercialize its pipeline. Their lead candidate, Rejoyn (CT-152), recently received FDA clearance as the first prescription digital therapeutic for the adjunctive treatment of Major Depressive Disorder symptoms.